Hepatitis C (HCV) is estimated to affect as many as 170 million people worldwide and an estimated 3.5 million people in the United States. Though HCV treatment has been in the news in recent years because of the breakthrough cures, treating Hepatitis C has always come with high costs when you include the onerous side effects of older therapies. Research conducted at the Schaeffer Center has analyzed the cost and value of these breakthrough drugs and their impact on the healthcare system and patients. For example:
Fox, D. S., & McCombs, J. S. (2016). Optimizing HCV treatment–Moving beyond the cost conundrum. Journal of hepatology.
Jena, A. B., Stevens, W., Gonzalez, Y. S., Marx, S. E., Juday, T., Lakdawalla, D. N., & Philipson, T. J. (2016). The wider public health value of HCV treatment accrued by liver transplant recipients.The American journal of managed care, 22(6 Spec No.), SP212-9.
Lakdawalla, D. N., Linthicum, M. T., & Vanderpuye-Orgle, J. (2016). Does patient cost sharing for HCV drugs make sense?. The American journal of managed care, 22(6 Spec No.), SP188-90.
Linthicum, M. T., Gonzalez, Y. S., Mulligan, K., Moreno, G. A., Dreyfus, D., Juday, T., ... & Brookmeyer, R. (2016). Value of expanding HCV screening and treatment policies in the United States. The American journal of managed care,22(6 Spec No.), SP227-35.
Matsuda, T., McCombs, J. S., Tonnu-Mihara, I., McGinnis, J., & Fox, D. S. The Impact of Delayed Hepatitis C Viral Load Suppression on Patient Risk: Historical Evidence from the Veterans Administration. In Forum for Health Economics and Policy.
Moreno, G. A., Mulligan, K., Huber, C., Linthicum, M. T., Dreyfus, D., Juday, T., ... & Lakdawalla, D. N. (2016). Costs and spillover effects of private insurers' coverage of hepatitis C treatment. The American journal of managed care, 22(6 Spec No.), SP236-44.
Tonnu-Mihara, I., Matsuda, T., McCombs, J., Saab, S., Hines, P., L’Italien, G., ... & Yuan, Y. (2016). Five Laboratory Tests Predict Patient Risk and Treatment Response in Hepatitis C: Veterans Affairs Data from 1999-2010. Universal Journal of Medical Science, 4(1), 10-20.
Cheetham, T. C., Niu, F., Chiang, K., Yuan, Y., Kalsekar, A., Hechter, R., ... & Nyberg, L. (2015). Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System. Journal of managed care & specialty pharmacy, 21(8), 641-647.
Van Nuys, K., Brookmeyer, R., Chou, J. W., Dreyfus, D., Dieterich, D., & Goldman, D. P. (2015). Broad hepatitis C treatment scenarios return substantial health gains, but capacity is a concern. Health Affairs, 34(10), 1666-1674.
Matsuda, T., McCombs, J., Tonnu-Mihara, I., Saab, S., Hines, P., LItalien, G. J., ... & Yuan, Y. (2014). The Impact Of Fibrosis On The Risk Of Long-Term Morbidity And Mortality In Chronic Hepatitis C Patients Treated In The Veterans Administration Health Care System. Value in Health, 17(3), A268.
McCombs, J., Matsuda, T., Tonnu-Mihara, I., Saab, S., Hines, P., L’Italien, G., ... & Yuan, Y. (2014). The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA internal medicine,174(2), 204-212.
McCombs, J. S., Yuan, Y., Shin, J., & Saab, S. (2011). Economic burden associated with patients diagnosed with hepatitis C. Clinical therapeutics,33(9), 1268-1280.
McHutchison, J. G., Manns, M., Patel, K., Poynard, T., Lindsay, K. L., Trepo, C., ... & Albrecht, J. K. (2002). Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C.Gastroenterology, 123(4), 1061-1069.